
Michael S. Eggert
Intensive Care Medicine | Pulmonary Medicine
600 Gresham Drive
Suite 8630 B
Norfolk, VA 23507
Suite 8630 B
Norfolk, VA 23507
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
Journal: Respiratory medicine
Published: June 18, 2025
Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry.
Journal: Pulmonary circulation
Published: October 26, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.
Journal: Pulmonary circulation
Published: December 09, 2021
BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
Journal: Pulmonary circulation
Published: October 15, 2021
Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry.
Journal: Pulmonary circulation
Published: June 23, 2021
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: April 26, 2018
Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document.
Journal: Pulmonary circulation
Published: July 04, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026